share_log

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Tonix Pharmaceuticals | 8-K：Tonix Pharmaceuticals宣佈在美國化學會 (ACS)2024年春季會議上進行海報展示，描述新型下一代催產素類似物的發現
SEC announcement ·  03/21 21:26
牛牛AI助理已提取核心訊息
Tonix Pharmaceuticals Holding Corp. (Tonix), a biopharmaceutical company, announced on March 21, 2024, the presentation of a poster at the American Chemistry Society (ACS) Spring 2024 Meeting, which took place from March 17 to March 21, 2024. The poster, titled 'Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations,' detailed the discovery of novel oxytocin analogues that may serve as treatments for craniofacial pain, excessive eating disorders including Prader Willi Syndrome, and certain endocrinological conditions. The company highlighted that these analogues have improved binding to magnesium, potentially eliminating the need for magnesium augmentation in their activity, unlike intranasal oxytocin. Tonix also reported ongoing Phase 2 studies of TNX-1900 for conditions such as pediatric obesity, binge eating disorder, bone health in autism, and social anxiety disorder. Additionally, TNX-2900 is being developed for Prader-Willi Syndrome and has received orphan drug designation from the FDA. The company aims to submit a New Drug Application (NDA) for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.
Tonix Pharmaceuticals Holding Corp. (Tonix), a biopharmaceutical company, announced on March 21, 2024, the presentation of a poster at the American Chemistry Society (ACS) Spring 2024 Meeting, which took place from March 17 to March 21, 2024. The poster, titled 'Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations,' detailed the discovery of novel oxytocin analogues that may serve as treatments for craniofacial pain, excessive eating disorders including Prader Willi Syndrome, and certain endocrinological conditions. The company highlighted that these analogues have improved binding to magnesium, potentially eliminating the need for magnesium augmentation in their activity, unlike intranasal oxytocin. Tonix also reported ongoing Phase 2 studies of TNX-1900 for conditions such as pediatric obesity, binge eating disorder, bone health in autism, and social anxiety disorder. Additionally, TNX-2900 is being developed for Prader-Willi Syndrome and has received orphan drug designation from the FDA. The company aims to submit a New Drug Application (NDA) for another candidate, Tonmya, for the management of fibromyalgia in the second half of 2024.
生物製藥公司Tonix Pharmicals Holding Corp.（Tonix）於2024年3月21日宣佈，將在2024年3月17日至3月21日舉行的美國化學學會（ACS）2024年春季會議上發佈海報。這張海報標題爲 “在低鎂配方中具有增強顱面抗感受作用的催產素類似物”，詳細介紹了新型催產素類似物的發現，這些類似物可以治療顱面疼痛、包括普拉德威利綜合症在內的過度飲食失調以及某些內分泌疾病。該公司強調，與鼻內催產素不同，這些類似物改善了與鎂的結合，有可能消除增強鎂活性的需要。Tonix 還報告了正在進行的針對兒科肥胖、暴飲暴食、自閉症骨骼健康和社交焦慮症等疾病的 TNX-1900 二期研究。此外，TNX-2900 正在開發用於治療普拉德-威利綜合症，並已獲得美國食品藥品管理局的孤兒藥認定。該公司的目標是在2024年下半年提交另一位候選人Tonmya的新藥申請（NDA），用於治療纖維肌痛。
生物製藥公司Tonix Pharmicals Holding Corp.（Tonix）於2024年3月21日宣佈，將在2024年3月17日至3月21日舉行的美國化學學會（ACS）2024年春季會議上發佈海報。這張海報標題爲 “在低鎂配方中具有增強顱面抗感受作用的催產素類似物”，詳細介紹了新型催產素類似物的發現，這些類似物可以治療顱面疼痛、包括普拉德威利綜合症在內的過度飲食失調以及某些內分泌疾病。該公司強調，與鼻內催產素不同，這些類似物改善了與鎂的結合，有可能消除增強鎂活性的需要。Tonix 還報告了正在進行的針對兒科肥胖、暴飲暴食、自閉症骨骼健康和社交焦慮症等疾病的 TNX-1900 二期研究。此外，TNX-2900 正在開發用於治療普拉德-威利綜合症，並已獲得美國食品藥品管理局的孤兒藥認定。該公司的目標是在2024年下半年提交另一位候選人Tonmya的新藥申請（NDA），用於治療纖維肌痛。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。